Seeking Alpha

CuraGen Corp. (CRGN)

()

Instablog posts on CRGN

  • Curagen – Positive Results at ASCO 2009 by Ohad Hammer
     Last month at the ASCO meeting, Curagen (CRGN) presented results for its lead drug, CR-011, in breast cancer and melanoma patients. CR011 had activity in both indications, however, most of the drug’s value should be ascribed to the breast cancer program, which represents a huge... More »
    July 7, 2009 • CRGN, CLDX, SGEN
  • FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO by Mike Havrilla
    Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
    May 31, 2009 • AZN, RHHBY.PK, OSIP
  • Todays update by dividendmachine
    recommended on my squidoo lens my long of the day crgn at the open .It opened at 1.35 and just crossed at 1.41 which is 4.44% in not even 10 minutes Dont fight the tape when trading
    May 29, 2009 • CRGN
  • Top 50 Surging Stocks 5/28 by MyHappyTrading.com
    From my spreadsheet. Top 50 surging stocks today. (Surge = unusually high volume combined with large price gain) Something happening with each of these. Determine cause before you buy. --- OCLS -- Oculus Innovative Sciences, Inc. -- Up 24.91% -- Rel Vol 5583% CRGN -- CuraGen Corp. -- Up 16.35%... More »
    May 28, 2009 • OCLS, WAVX, CRGN
  • Top picks for ASCO 2009 (Part II) by Ohad Hammer
    Click here for Part 1 Seattle Genetics – Another step towards approval Seattle Genetics (SGEN) will present results from a phase I trial of SGN-35 in two rare blood cancers. This agent is important not only because it represents Seattle Genetics’ first opportunity for... More »
    May 27, 2009 • SGEN, IMGN, MITI
  • Top picks for ASCO 2009 (Part I) by Ohad Hammer
    The ASCO annual meeting, one of the most important events in the pharmaceutical industry will take place in Orlando next weekend. With over 4,000 abstracts to be presented this year, separating the wheat from the chaff is difficult, but below is an incomplete list of intriguing trials that... More »
    May 27, 2009 • PFE, CRGN, SGEN
  • Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches by Mike Havrilla
    Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
    May 17, 2009 • ALTH, CRGN, CTIC
  • Micromet – The Plot Thickens by Ohad Hammer
     The past 12 months have been anything but boring for Micromet’s shareholders (MITI). Last summer, Micromet’s stock climbed to $7 following excellent clinical data (discussed here) and a landmark publication in Science Magazine (discussed here), but since then the company has... More »
    April 23, 2009 • MITI, IMGN, SGEN

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.